| Literature DB >> 31463517 |
Carolina Bigert1,2, Jan Ivar Martinsen3, Per Gustavsson4,5, Pär Sparén6.
Abstract
OBJECTIVES: To evaluate cancer incidence among Swedish firefighters and analyze risk in relation to work duration as a proxy for cumulative exposure.Entities:
Keywords: Cancer incidence; Carcinogens; Firefighters; Occupational exposure; Smoke
Mesh:
Year: 2019 PMID: 31463517 PMCID: PMC7007886 DOI: 10.1007/s00420-019-01472-x
Source DB: PubMed Journal: Int Arch Occup Environ Health ISSN: 0340-0131 Impact factor: 3.015
Characteristics of the Swedish firefighter cohort (n = 8136) and information on start, end and duration of the follow-up.
Follow-up period 1961–2009
| Percent | ||
|---|---|---|
| Emigration and Vital status Dec 31 2009 | ||
| Emigrated | 13 | 0.2 |
| Dead | 2314 | 28.4 |
| Alive | 5809 | 71.4 |
| Year of birth (min: 1896, max: 1960, mean: 1940) | ||
| < 1920 | 1082 | 13.3 |
| 1920–1929 | 1140 | 14.0 |
| 1930–1939 | 898 | 11.0 |
| 1940–1949 | 2424 | 29.8 |
| 1950–1960 | 2592 | 31.9 |
| Start of follow-up | ||
| 1961 | 2290 | 28.2 |
| 1971 | 961 | 11.8 |
| 1981 | 2504 | 30.8 |
| 1991 | 2381 | 29.2 |
| End of follow-up (min: 1961, max: 2009, mean: 2004) | ||
| 1961–1969 | 89 | 1.1 |
| 1970–1979 | 239 | 2.9 |
| 1980–1989 | 436 | 5.3 |
| 1990–1999 | 713 | 8.8 |
| 2000–2009 | 6659 | 81.9 |
| Age at start of follow-up (min: 30, max: 64, mean: 37) | ||
| 30–39 | 6950 | 85.4 |
| 40–49 | 731 | 9.0 |
| 50–59 | 398 | 4.9 |
| 60–64 | 57 | 0.7 |
| Age at end of follow-up (min: 31, max: 100, mean: 65) | ||
| 30–39 | 33 | 0.4 |
| 40–49 | 295 | 3.6 |
| 50–59 | 2658 | 32.7 |
| 60–69 | 2717 | 33.4 |
| 70+ | 2433 | 29.9 |
| Duration of follow-upa (min: 0.02, max: 49, mean: 28) (years) | ||
| > 0–9 | 173 | 2.1 |
| 10–19 | 2693 | 33.1 |
| 20–29 | 2884 | 35.5 |
| 30–39 | 1394 | 17.1 |
| 40+ | 992 | 12.2 |
| Number of censuses where registered as a firefighter | ||
| 1 | 2583 | 31.8 |
| 2 | 3029 | 37.2 |
| 3 | 2168 | 26.6 |
| 4 | 356 | 4.4 |
aDoes not represent the number of years working as a firefighter but rather the stratified follow-up periods
Cancer incidence among 8136 male Swedish firefighters.
Follow-up 1961–2009
| ICD-10 | Cancer site | Obs | Exp | SIR | 95% CI |
|---|---|---|---|---|---|
| C09–14 | Pharynx | 13 | 12.5 | 1.04 | 0.55–1.78 |
| C15 | Esophagus | 13 | 18.4 | 0.71 | 0.38–1.21 |
| C16 | Stomach | 60 | 55.4 | 1.08 | 0.83–1.39 |
| C18 | Colon | 101 | 100 | 1.01 | 0.82–1.23 |
| C19–21 | Rectum, rectosigma | 63 | 70.6 | 0.89 | 0.69–1.14 |
| C22 | Primary liver | 15 | 16.9 | 0.89 | 0.50–1.47 |
| C25 | Pancreas | 43 | 36.6 | 1.17 | 0.85–1.58 |
| C32 | Larynx | 12 | 13.0 | 0.92 | 0.48–1.61 |
| C34 | Lung | 110 | 125 | 0.87 | 0.72–1.05 |
| Adenocarcinoma | 31 | 30.7 | 1.01 | 0.69–1.43 | |
| Small cell | 10 | 13.9 | 0.72 | 0.34–1.32 | |
| Squamous cell | 38 | 40.7 | 0.93 | 0.66–1.28 | |
| Other | 31 | 40.5 | 0.77 | 0.52–1.09 | |
| C45 | Mesothelioma | 7 | 6.30 | 1.11 | 0.45–2.29 |
| C61 | Prostate | 444 | 420 | 1.06 | 0.96–1.16 |
| C62 | Testis | 4 | 10.2 | 0.39 | 0.11–1.01 |
| C64 | Kidney | 41 | 48.6 | 0.84 | 0.61–1.14 |
| C66-68 | Bladder | 109 | 101 | 1.08 | 0.89–1.31 |
| C43 | Melanoma skin | 69 | 56.6 | 1.22 | 0.95–1.54 |
| C44 | Non-melanoma skin | 101 | 68.3 | 1.48 | 1.20–1.80 |
| C70–72 | Brain | 38 | 42.5 | 0.89 | 0.63–1.23 |
| Glioma | 18 | 19.2 | 0.94 | 0.56–1.48 | |
| C49 | Soft tissue | 15 | 10.3 | 1.46 | 0.82–2.41 |
| C83, C85 | Non-Hodgkin lymphoma | 42 | 40.2 | 1.05 | 0.75–1.41 |
| C90 | Multiple myeloma | 26 | 20.8 | 1.25 | 0.82–1.83 |
| C91–95 | Leukemia | 33 | 34.9 | 0.94 | 0.65–1.33 |
| Chronic lymphatic | 14 | 16.4 | 0.85 | 0.47–1.43 | |
| C00–99 | All cancers | 1483 | 1438 | 1.03 | 0.97–1.09 |
Obs observed number of cases, Exp expected number of cases, SIR standardized incidence ratio, CI confidence interval
Observed number of cases for selected cancer sites and standardized incidence ratio among 8136 male Swedish firefighters, by duration of employment.
Follow-up 1961–2009
| ICD-10 | Cancer site | 1–9 years | 10–19 years | 20–29 years | 30 + years | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Obs | SIR | 95% CI | Obs | SIR | 95% CI | Obs | SIR | 95% CI | Obs | SIR | 95% CI | |||
| C16 | Stomach | 4 | 1.43 | 0.39–3.66 | 22 | 1.23 | 0.77–1.86 | 18 | 1.00 | 0.59–1.57 | 16 | 0.97 | 0.55–1.58 | |
| C34 | Lung | 3 | 1.03 | 0.21–3.01 | 33 | 1.06 | 0.73–1.48 | 34 | 0.85 | 0.59–1.18 | 40 | 0.78 | 0.56–1.06 | |
| Adenocarcinoma | 1 | 2.59 | 0.07–14.4 | 8 | 1.32 | 0.57–2.60 | 6 | 0.65 | 0.24–1.41 | 16 | 1.06 | 0.61–1.72 | ||
| C45 | Mesothelioma | 1 | 13.68 | 0.35–76.2 | 0 | 0.00 | 0.00–2.80 | 3 | 1.46 | 0.30–4.28 | 3 | 1.04 | 0.21–3.04 | |
| C61 | Prostate | 2 | 0.50 | 0.06–1.81 | 76 | 0.94 | 0.74–1.18 | 114 | 0.98 | 0.81–1.17 | 252 | 1.14 | 1.01–1.29 | |
| C43 | Melanoma skin | 0 | 0.00 | 0.00–2.30 | 17 | 1.24 | 0.72–1.98 | 27 | 1.42 | 0.94–2.07 | 25 | 1.11 | 0.72–1.65 | |
| C44 | Non-melanoma skin | 0 | 0.00 | 0.00–3.70 | 28 | 1.82 | 1.21–2.62 | 35 | 1.56 | 1.09–2.17 | 38 | 1.28 | 0.91–1.76 | < |
| C83, C85 | Non-Hodgkin lymphoma | 1 | 0.88 | 0.02–4.89 | 12 | 1.10 | 0.57–1.93 | 17 | 1.17 | 0.68–1.87 | 12 | 0.88 | 0.45–1.53 | |
| C90 | Multiple myeloma | 0 | 0.00 | 0.00–7.24 | 4 | 0.77 | 0.21–1.96 | 8 | 1.17 | 0.51–2.31 | 14 | 1.70 | 0.93–2.85 | |
| C00–99 | All cancers | 27 | 0.81 | 0.53–1.18 | 349 | 1.01 | 0.92–1.14 | 461 | 1.03 | 0.94–1.13 | 646 | 1.04 | 0.97–1.13 | |
Italic values indicate p trend; < 0.05 was considered statistically significant
Obs observed number of cases, SIR standardized incidence ratio, CI confidence interval
*There was a statistically significant trend of decreasing risk with increasing employment duration
Observed number of cases for selected cancer sites and standardized incidence ratios among 8136 male Swedish firefighters, by time period.
Follow-up 1961–2009
| ICD-10 | Cancer site | 1961–1975 | 1976–1990 | 1991–2009 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Obs | SIR | 95% CI | Obs | SIR | 95% CI | Obs | SIR | 95% CI | ||
| C16 | Stomach | 16 | 1.85 | 1.06–3.00 | 22 | 1.16 | 0.73–1.76 | 22 | 0.79 | 0.49–1.19 |
| C34 | Lung | 11 | 0.94 | 0.47–1.68 | 32 | 0.84 | 0.58–1.19 | 67 | 0.88 | 0.68–1.12 |
| Adenocarcinoma | 2 | 1.50 | 0.18–5.40 | 6 | 0.87 | 0.32–1.90 | 23 | 1.02 | 0.65–1.53 | |
| C45 | Mesothelioma | 0 | 0.00 | 0.00–19.0 | 2 | 1.29 | 0.16–4.67 | 5 | 1.10 | 0.36–2.56 |
| C61 | Prostate | 8 | 0.68 | 0.29–1.34 | 77 | 1.09 | 0.86–1.36 | 359 | 1.06 | 0.95–1.18 |
| C43 | Melanoma skin | 5 | 1.56 | 0.51–3.65 | 14 | 1.10 | 0.60–1.85 | 50 | 1.23 | 0.91–1.62 |
| C44 | Non-melanoma skin | 2 | 0.87 | 0.11–3.16 | 15 | 1.28 | 0.71–2.11 | 84 | 1.55 | 1.23–1.92 |
| C83, C85 | Non-Hodgkin lymphoma | 1 | 0.35 | 0.01–1.97 | 10 | 0.84 | 0.40–1.54 | 31 | 1.22 | 0.83–1.73 |
| C90 | Multiple myeloma | 2 | 1.17 | 0.14–4.21 | 6 | 1.07 | 0.39–2.32 | 18 | 1.34 | 0.79–2.11 |
| C00–99 | All cancers | 95 | 0.96 | 0.78–1.18 | 352 | 1.03 | 0.93–1.15 | 1036 | 1.04 | 0.97–1.10 |
Obs observed number of cases, SIR standardized incidence ratio, CI confidence interval